Ken Griffin Cue Biopharma, Inc. Call Options Transaction History

Citadel Advisors LLC

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2025 May 15, 2025	SELL	$0.91 - $1.75 $637 - $1,225	-700 Reduced 6.48%	10,100 $9,000
Q4 2024 Feb 14, 2025	SELL	$0.71 - $1.88 $2,556 - $6,768	-3,600 Reduced 25.0%	10,800 $11,000
Q3 2024 Nov 14, 2024	BUY	$0.45 - $1.08 $720 - $1,728	1,600 Added 12.5%	14,400 $10,000
Q2 2024 Aug 14, 2024	SELL	$1.24 - $2.18 $124 - $218	-100 Reduced 0.78%	12,800 $15,000
Q1 2024 May 15, 2024	SELL	$1.77 - $3.09 $16,638 - $29,046	-9,400 Reduced 42.15%	12,900 $24,000
Q4 2023 Feb 14, 2024	BUY	$1.72 - $3.1 $12,556 - $22,630	7,300 Added 48.67%	22,300 $58,000
Q3 2023 Nov 14, 2023	BUY	$2.23 - $4.69 $3,568 - $7,504	1,600 Added 11.94%	15,000 $34,000
Q2 2023 Aug 14, 2023	SELL	$3.11 - $4.91 $47,894 - $75,614	-15,400 Reduced 53.47%	13,400 $48,000
Q1 2023 May 15, 2023	BUY	$2.41 - $3.74 $54,707 - $84,898	22,700 Added 372.13%	28,800 $102,000
Q4 2022 Feb 14, 2023	SELL	$2.39 - $3.95 $18,164 - $30,020	-7,600 Reduced 55.47%	6,100 $17,000
Q3 2022 Nov 14, 2022	SELL	$2.23 - $3.37 $18,732 - $28,308	-8,400 Reduced 38.01%	13,700 $31,000

11.5M

10.1K

1.4K

Ticker CUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,381,700
Market Cap $24.8M
Description
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.